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BY-NC-ND license (http://creativecomBackground/purpose: Evidence on clinical effectiveness of metformin in ethnic Chinese
women with polycystic ovary syndrome (PCOS) remains scarce. Standard diagnostic approaches
to identify insulin resistance (IR) cases in PCOS patients might be invasive, labor intensive, and
stressful for patients (i.e., euglycemic clamp), or somewhat complicated for clinicians to
calculate and monitor in routine practice [i.e., the homeostatic model assessment (HOMA)
and quantitative insulin sensitivity check index (QUICKI)]. The aim of this study was to evaluate
the clinical effects of metformin in Taiwanese women with PCOS and identify the feasible diag-
nostic measures of IR for Taiwanese women with PCOS.
Methods: A total of 114 women from a medical center in Taiwan were studied. All were aged
between 18 years and 45 years, diagnosed with PCOS according to the Rotterdam criteria, and
treated with metformin. Outcome end points were body mass index (BMI) and 2-hour postload
glucose and insulin levels from a 75-g oral glucose tolerance test.
Results: BMI in overweight patients were significantly improved with metformin treatment
duration (p < 0.001). The 2-hour insulin level statistically improved after treatment (before:
80.7  63.9 mIU/mL vs. after: 65.0  60.4 mIU/mL; p Z 0.009). The improved 2-hour insulin
level was significantly greater in IR patients than in non-IR patients. Compared with the 2-
hour postload insulin level, the fasting insulin level provided 18.15% sensitivity and 94.12%
specificity, the HOMA yielded 40% sensitivity and 70.58% specificity, and the QUICKI achieved
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Effect of metformin treatment for Taiwanese women with PCOS 81Conclusion: Clinical outcomes in Taiwanese PCOS women were improved with metformin
treatment, especially in overweight and IR patients. The 2-hour postload insulin level appears
to be a convenient tool for screening IR in Taiwanese patients.
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Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder of reproductive-age women, approxi-
mately affecting 8.7e11.9% of such individuals, which de-
pends on diagnostic criteria [i.e., National Institutes of
Health (NIH) criteria, Rotterdam consensus criteria, and
Androgen Excess Society criteria].1 According to the Rot-
terdam criteria, 5.6% of Chinese women suffer from PCOS.2
The common clinical presentations associated with this
syndrome are obesity, menstrual disorders, acne, hirsutism,
and alopecia.3 Around 60e70% of women with PCOS have
insulin resistance (IR).4 Obese women with PCOS have
significantly more severe IR levels than nonobese women
with PCOS.5 Because of the high prevalence of IR, women
with PCOS are prone to metabolic syndromes,6 such as
obesity, impaired glucose tolerance (IGT), and gestational
and Type 2 diabetes, and have an increased risk of car-
diovascular diseases.7
A biguanide medication, metformin, reduces insulin
secretion and hyperinsulinemia, and improves insulin sensi-
tivity, ovary function, and associated metabolic syndromes.8
Although metformin use for PCOS is still considered “off-
label” by the Food and Drug Administration, it is commonly
prescribed for women with PCOS,9 especially for those with
IR.10 Some studies have demonstrated that metformin im-
proves glucose effectiveness,11 insulin sensitivity, menstrual
cyclicity, fertility, and live-birth rates, and reduces clinical
hyperandrogenism (i.e., acne),9,12 whereas another study
did not find such clinical benefits of metformin when used
for PCOS.13 However, evidence on clinical effects of met-
formin in Chinese women with PCOS remains limited.
Recently, Li et al’s study14 of 47 metformin-treated PCOS
women from China showed significantly lower 2-hour insulin
levels in oral glucose tolerance test (OGTT) and an
improvement in insulin sensitivity as shown by the significant
decrease in the homeostatic model assessment (HOMA) of IR
after 6 months of treatment.
Adherence to treatment is a key for ensuring drug
response and effectiveness in patients.15 In previous studies
on patients with Type 2 diabetes, patients’ adherence with
metformin was found to be suboptimal and to decrease
with time,16,17 mostly due to its side effects [i.e., gastro-
intestinal (GI) intolerance]. Few studies have assessed
medication adherence issues in PCOS women.18,19 Identi-
fying the factors associated with medication adherence is
important for developing treatment education and in-
terventions to enhance patients’ drug compliance and
ensure the effectiveness of treatment in clinical practice.15
It is thus important for researchers to elucidate the
adherence behavior in PCOS women and assess the factors
associated with their medication adherence.Several diagnostic approaches have been applied to
assess IR in PCOS women. Some direct measures typically
require an intervention (e.g., administrate insulin) to assess
the ability of insulin to dispose glucose, including the
euglycemic clamp and intravenous glucose tolerance test/
OGTT.20 However, they are usually invasive, labor intensive,
and stressful for patients. Surrogate methods assess the
fasting insulin level and glucose-to-insulin (G/I) ratio to es-
timate insulin action.20 These methods are more rapid, less
invasive, and require less time and skill to perform. How-
ever, fasting insulin levels and G/I ratios do not accurately
reflect insulin sensitivity.21 The HOMA and the quantitative
insulin sensitivity check index (QUICKI) scores can be
calculated based on the fasting glucose and fasting insulin
concentrations to determine IR. However, they may not be
feasible for clinicians to calculate in practice. Saxena et al22
studied Indian women with PCOS and showed that the 2-hour
postglucose-load insulin level from OGTT is a cost-effective,
convenient, and reliable marker for IR, especially in
resource-constrained developing countries. Future research
is thus warranted to determine whether the OGTT is a
convenient tool for screening IR in Taiwanese PCOS patients.
The present study therefore aims to (1) examine the
clinical effectiveness of metformin in Taiwanese women
with PCOS, stratifying the effects by patients’ character-
istics, namely, body mass index (BMI; overweight vs.
normal), glucose tolerance (IGT vs. normal), and insulin
sensitivity (IR vs. normal); (2) evaluate patients’ adherence
to metformin and the factors associated with metformin
treatment duration for women with PCOS; and (3) identify a
feasible and convenient approach (i.e., fasting insulin,
HOMA, QUICKI, 2-hour postload insulin from OGTT) to
determine IR in PCOS women in clinical practice.Materials and methods
A retrospective cohort study was conducted to evaluate the
clinical effectiveness of metformin by reviewing medical
charts in the National Cheng Kung University Hospital from
October 2004 to December 31, 2011. Permission for the study
from the Institutional Review Board of the National Cheng
Kung University Hospital was obtained before the study
commencement (A-ER-103-287). Because this retrospective
study analyzed and reported the data anonymously, no
informed consent was obtained from the study participants.
Participants
The study cohort was aged between 18 years and 45 years
and diagnosed with PCOS during the period from January 1,
2005, to December 31, 2010, according to the Rotterdam
82 H.-t. Ou et al.criteria23 in which PCOS was defined by the presence of at
least two of the following three criteria: (1) oligo-
anovulation (a cycle length > 35 days or amenorrhoea),
(2) clinical hyperandrogenism (hirsutism recorded as
modified FerrimaneGallwey score  6 with/without acne or
androgenic alopecia) and/or biochemical hyper-
androgenism (total testosterone level > 0.95 ng/mL), and
(3) polycystic ovaries ( 12 follicles measuring 2e9 mm in
diameter, or ovarian volume > 10 mL in at least one ovary).
We excluded those (1) diagnosed with similar clinical pre-
sentations, including congenital adrenal hyperplasia,
hyperprolactinemia, androgen-secreting tumors, Cushing
syndrome, abnormal thyroid function, and thyroid disease;
(2) diagnosed with diabetes, fasting plasma glucose level of
126 mg/dL or more, 2-hour glucose level of 200 mg/dL or
more, or HbA1c greater than 7 before PCOS diagnosis; (3)
taking any medications that may influence the insulin or/
and glucose level, including metformin and other antidia-
betic drugs, or oral contraceptive pills 3 months prior to
PCOS diagnosis. All patients were treated with metformin
(Glucophage, 500 mg t.i.d. for at least 6 months) after
PCOS diagnosis (new users of metformin). Patients who
cannot tolerate the immediate-release formulation (i.e.,
due to GI intolerance side effects) can switch to extended-
release (XR) metformin (C.T.L. XR). Although no study re-
ported similar efficacy between XR and immediate-release
metformin in PCOS women, several studies in patients with
Type 2 diabetes have shown that XR metformin is as effec-
tive as immediate-release metformin to achieve glycemic
control in patients newly started on metformin as well as in
those switched from the immediate-release for-
mulation.24e26 Every patient was observed from the initia-
tion of metformin treatment to (1) lost to follow-up, (2) the
end of metformin treatment, or (3) the end of 2011. The use
of metformin was examined as the length of metformin
treatment duration and medication adherence, expressed as
the medication possession ratio (MPR). The MPR expresses
the percentage of day’s supply received divided by a period,
implying the percentage of time a patient received a
medication (i.e., metformin in this case). The MPR values
were calculated by summing day’s supply from the first to
the last prescription divided by time between the last pre-
scription date plus day’s supply and the first prescription
date ½total days supply=ðlast fill date first fill dateþ
last fill days supplyÞ27,28 for all patients within a year from
the beginning of metformin treatment. The MPR values
range from 0 to 1, with higher values indicating better
adherence.Effectiveness outcomes
There were three clinical outcomes of interest, including
BMI and 2-hour postload glucose and insulin levels from a
standardized 75-g oral OGTT, which were measured every
time patients returned for a visit. BMI was estimated as
weight divided by height squared. All patients received a
75-g glucose monohydrate in 350 mL water after an 8-hour
overnight fasting. A total of 5 mL blood sample was drawn
before glucose loading and another 5-mL blood sample was
drawn at 120 minutes after the glucose loading. Plasma
glucose and insulin concentrations were determined by theglucose oxidase method using a glucose analyzer (Model
2300; YSI, Yellow Springs, OH, USA) and an automated
chemiluminescence system (ADVIA Centaur Immunoassay
System, Siemens Healthcare Diagnostics, Deerfield, IL,
USA), respectively. Other biochemical assessments
included complete hormonal evaluation, including serum
follicle-stimulating hormone, luteinizing hormone, thyroid-
stimulating hormone, prolactin, estradiol (E2), total
testosterone, and sex hormone-binding globulin, which
were measured on Days 3e5 during patients’ menstrual
period and analyzed by RIA kit from Diagnostic Products
(Los Angeles, CA, USA). The HbA1c level was measured by
boronate affinity chromatography (Bio-Rad Laboratories,
Inc., Hercules, CA, USA).Analytic analyses
Descriptive analyses were used to present the de-
mographics of the study population, medication use, and
outcomes of interest. Mixed-effect models were applied to
assess the effect of metformin (treatment duration and
MPR) on the repeated outcomes measure (i.e., BMI) every
3 months in the follow-up. The 2-hour glucose and insulin
levels before and after metformin treatment was initiated
were evaluated using the paired t test. The study popula-
tion was also stratified by (1) BMI (normal: BMI < 25 kg/m2
vs. overweight: BMI  25 kg/m2, and an additional sensi-
tivity analysis: normal: BMI < 27 kg/m2 vs. overweight: BMI
 27 kg/m2); (2) 2-hour postload glucose level (a cutoff
point  140 mg/dL to classify IGT vs. normal); and (3) 2-
hour postload insulin level (a cutoff point  35 mIU/mL to
classify IR vs. normal) in the OGTT. Although there is no
consensus on a cutoff point of the 2-hour insulin level to
define IR, Stovall et al21 showed that the means of the 2-
hour postload insulin level for nonoverweight
(BMI < 25 kg/m2) and overweight (BMI  25 kg/m2) patients
were 34.2 mIU/mL and 70.0 mIU/mL, respectively.21 In
addition, Saxena et al22 used a value of 2-hour insulin level
greater than 41 mIU/mL to determine the presence of IR in
Indian women with PCOS.22 We selected a cutoff point of 2-
hour insulin level of 35 mIU/mL or more based on the range
of 2-hour postload insulin levels in Stovall et al’s study21
(34.2e70.0 mIU/mL) and our laboratory at the National
Cheng Kung University Hospital. The low cutoff point value
of 2-hour postload insulin (i.e., 35 mIU/mL) we used might
reduce the bias of study findings toward a falsely low rate
of IR. The difference in difference test was applied to
assess the change in glucose (or insulin) levels before and
after metformin treatment between subgroups (i.e., IGT
and normal patients, IR, and normal patients), with
adjustment for the baseline patients’ characteristics and
medication use [i.e., metformin treatment duration
(MPR)]. Furthermore, using the 2-hour insulin level (with a
value of  35 mIU/mL defined as IR cases) from the OGTT as
a standard to identify IR cases, we estimated the sensitivity
and specificity of the fasting insulin (with a
threshold > 20 mIU/mL defined as IR21,29), HOMA30 (with a
value  2.14 defined as IR31), and QUICKI32 (with a
value  0.34 defined as IR31). A receiver-operating char-
acteristic (ROC) curve was plotted to compare the HOMA
and QUICKI with the OGTT in the prediction of IR cases.
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Statistical Analysis System 9.4 (SAS Institute Inc., Cary, NC,
USA) was used for the aforementioned statistical analyses.Results
A total of 114 patients were included (Figure 1), with an
average age of 27.1 years, 37% with BMI of 25 kg/m2 or
more, 38% with IGT, and 66% with IR. All eligible women
(n Z 114) had baseline examination and had return office
visits of at least two times after PCOS diagnosis. Of them,
72 women had complete data on fasting glucose and insulin
levels and 2-hour glucose and insulin levels. All study par-
ticipants started with immediate-release metformin (Glu-
cophage) and then 41% of patients switched to XR
metformin (C.T.L. XR) in follow-up. The detailed baseline
characteristics of the study population are presented in
Table 1. Supplementary Table S1 online presents the de-
mographics of obese subgroups with various cutoff values of
BMI. In multivariate analysis, XR metformin use was signif-
icantly associated with treatment duration of metformin;
compared with immediate-release metformin users, those
with the XR form of metformin treatment had 3.29 monthsFigure 1 Flowchart of study population selelonger metformin treatment (p Z 0.003; Table 2). In
addition, patients who received the XR form showed better
adherence to metformin than those who received the
immediate-release form; the average value of MPR in the
users of XR form (MPRZ 0.89) was significantly higher than
that in those of the immediate-release form (MPR Z 0.70;
p < 0.001). Using a cutoff point of MPR of 0.85 or over for
stratifying adherence and nonadherence,33 87% of patients
with XR had MPR values greater than 0.85, whereas only 53%
of those with immediate-release form had values of 0.85 or
more. Table 3 indicates significant improvement in BMI in
overweight and obese women with PCOS, whereas this was
not significant in PCOS women with normal weight.
Figure 2A and 2B indicate that the 2-hour glucose and in-
sulin levels decreased after metformin treatment. Although
the change in the 2-hour glucose level was not statistically
significant (baseline: 112.0  27.2 mg/dL vs.
113.0  32.2 mg/dL, p Z 0.75; Figure 2A), the improved
2-hour insulin level after metformin treatment was statis-
tically significant (baseline: 80.7  63.9 mIU/mL vs.
65.0  60.4 mIU/mL, pZ 0.009; Figure 2B). A plot of 2-hour
post-load glucose/insulin ratio was also provided in Sup-
plementary Figure S3. IGT and IR patients had significantly
improved 2-hour glucose and insulin levels after metforminction. PCOS Z polycystic ovary syndrome.
Table 1 Demographics of study population.
Characteristics All
(n Z 114)
Subgroups
Nonoverweight
(BMI < 25 kg/m2)
(n Z 59)
Overweight
(BMI  25 kg/m2)
(n Z 55)
Normal
(n Z 71)
Impaired glucose tolerance
(n Z 43)
Normal
(n Z 39)
Insulin resistance
(n Z 75)
Biometric
Age (yr) 27.1  4.7 26.7  4.1 27.8  5.2 26.3  4.8 26.9  3.7 25.5  5.1 26.7  4.5
Weight (kg) 64.2  15.5 53.6  6.5 78.6  13.8* 65.9  16.8 70.6  6.2 58.1  11.9 68.7  17.3**
BMI (kg/m2) 25.1  5.8 21.0  2.2 30.9  4.7* 25.8  6.2 27.5  7.4 23.3  5.4 26.7  0.78**
Systolic BP (mmHg) 118.3  17.7 109.4  10.9 127.5  19.0* 117.7  17.5 130.4  23.9** 117.2  15.9 120.4  19.1
Diastolic BP (mmHg) 72.6  13.0 66.0  8.0 79.9  13.2* 72.0  12.7 82.1  18.8** 68.8  13.5 74.3  13.7
m-FG score 4.1  3.4 3.9  2.8 4.4  4.0 4.9  3.8 1.8  1.3** 6.1  4.8 4.2  3.3
Hormones
TSH (mIU/mL) 1.98  0.84 1.81  0.70 2.08  0.88 1.97  0.83 2.26  1.00 2.16  0.90 1.98  0.82
LH (mIU/mL) 9.70  5.92 11.17  6.40 7.52  4.03** 8.94  5.21 8.00  5.49 9.66  4.56 8.66  5.36
FSH (mIU/mL) 6.28  2.06 6.14  1.88 6.21  2.12 6.14  1.94 6.08  2.09 6.24  1.72 6.05  2.02
LH/FSH 1.39  0.49 1.67  0.53 1.21  0.27 1.36  0 .43 1.17  0.51 1.48  0.33 1.29  0.46
Estradiol (E2, pg/mL) 52.64  42.48 46.59  31.07 56.81  53.65 50.00  32.27 52.85  22.26 45.99  37.67 51.60  29.07
PRL (ng/mL) 10.31  4.31 10.65  4.33 9.58  4.21 10.50  4.12 8.86  3.67 9.40  2.70 10.60  4.34
TT (ng/mL) 0.54  0.28 0.48  0.25 0.60  0.30** 0.59  0.30 0.62  0.36 0.51  0.26 0.61  0.29
Glycemic parameters
2-h glucose (mg/dL) 109.6  27.9 102.4  27.5 120.4  27.3** 104.5  17.9 166.1  15.9* 91.4  17.0 117.0  26.7*
2-h insulin (mIU/mL) 72.4  59.5 50.3  32.1 106.1  76.5* 69.2  51.5 159.6  91.3** 18.1  9.5 97.0  61.9*
Clinical presentation
Biochemical
hyperandrogenism
17 (11.4) 4 (6.8) 10 (18.2) 12 (16.9) 2 (20.0) 2 (11.8) 11 (16.9)
Hirsutism 30 (27.0) 13 (28.3) 11 (25.6) 21 (34.4) 0 (0.0) 8 (53.3) 14 (25.9)
Acne 72 (48.3) 29 (49.2) 27 (49.1) 29 (41.4) 5 (50.0) 6 (75.0) 28 (65.1)
Irregular menses 96 (84.2) 45 (76.3) 51 (92.7) 58 (81.7) 38 (88.4) 31 (79.5) 64 (85.3)
Except for clinical presentation [presented as n (%)], all other data are presented as mean  standard deviation. The n (%) refers to the number of patients with a given clinical condition
(i.e., biochemical hyperandrogenism) and the percentage of patients with a given condition. Patients with irregular menses were treated as oligomenorrhea and amenorrhea cases.
* p  0.0001.
** p  0.05.
BMI Z body mass index; BP Z blood pressure; FSH Z follicle-stimulating hormone; LH Z luteinizing hormone; m-FG Z modified FerrimaneGallwey; PRL Z prolactin; TSH Z thyroid-
stimulating hormone; TT Z total testosterone.
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Table 2 Factors associated with treatment duration of
metformin for women with PCOS.
Coefficient
(standard error)
p
Outcome: metformin treatment duration (month)
Univariate analysis
Weight (kg) 0.092 (0.032) 0.005
BMI (kg/m2) 0.259 (0.087) 0.003
Overweight (BMI  25 kg/m2)
(ref. normal weight)
2.264 (1.023) 0.029
Metformin extended-release
(ref. immediate-release)
4.068 (1.019) 0.0001
Marital status (ref. married) 2.184 (1.017) 0.033
Pregnancy intention (ref. no
pregnancy intention or plan)
2.183 (1.034) 0.036
Multivariate analysis (R2 Z 0.146)
Metformin extended-release
(ref. immediate-release)
3.288 (1.066) 0.003
BMI Z body mass index; PCOS Z polycystic ovary syndrome;
ref. Z reference.
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(Table 4). A total of 72 cases had complete values of the
fasting glucose, fasting serum insulin (from which the HOMA
and QUICKI could be calculated), and 2-hour postload in-
sulin from the OGTT. The ROC curves were 0.562 [95%
confidence interval (CI) 0.4842e0.6388], 0.552 (95% CI
0.4236e0.6823), and 0.6230 (95% CI 0.5213e0.7247) for the
fasting insulin, HOMA and QUICKI, respectively (see
Supplementary Figure S1 online). As compared with the 2-
hour postload insulin level, the fasting insulin levelTable 3 Mixed effect models for assessing the effect of metfor
All
(n Z 114) Nonoverweight
(BMI < 25 kg/m2)
(n Z 59)
(BM
Estimate
(standard
error)
p Estimate
(standard
error)
p Estim
(stan
error
Intercept 25.80 (0.58) <0.0001 21.06 (0.28) <0.0001 30.9
Metformin
treatment
duration
0.002 0.63
3 mo (ref.
baseline)
0.05 (0.30) 0.88 0.18 (0.35) 0.61 0.5
6 mo (ref.
baseline)
0.39 (0.30) 0.19 0.13 (0.35) 0.71 1.0
9 mo (ref.
baseline)
0.50 (0.31) 0.11 0.02 (0.35) 0.96 1.2
Medication
possession
ratio
0.49 (0.32) 0.13 0.53 (0.38) 0.16 0.1
The mixed effect models were adjusted for blood pressures, LH, TT,
different between nonoverweight and overweight patients at baselin
BMI Z body mass index; LH Z luteinizing hormone; TT Z total testoprovided 18.15% sensitivity and 94.12% specificity, the
HOMA had 40% sensitivity and 70.58% specificity, and the
QUICKI achieved 63.63% sensitivity and 11.76% specificity.
Discussion
This study showed that metformin significantly improved IR
and BMI, especially in overweight and IR women affected by
PCOS. Our results support the recommendations advocated
by the 2013 Endocrine Society Clinical Guideline,8 which
indicates that for women with PCOS, metformin is recom-
mended for overweight, IR, or IGT cases. In addition, the XR
metformin that has lower GI side effects and pill burden
(i.e., once-daily dosing), compared with the conventional
immediate-release formulation, appeared to enhance pa-
tients’ adherence to treatment.
Comparison with previous research on women with
PCOS
Several international studies recently evaluated the clinical
effectiveness of metformin for women with PCOS. Fux Otta
et al34 conducted a randomized, double-blind, and
placebo-controlled trial for 4 months to examine the ef-
fects of metformin versus a placebo, in addition to diet and
exercise, on endocrine and metabolic disturbances in 30
Argentine women with PCOS (20e34 years old), where the
definition of PCOS diagnosis followed the NIH criteria. A
prospective observational study in India was carried out by
Saxena et al35 on 40 infertile women (aged 18e38 years)
with PCOS (confirmed by the Rotterdam criteria). All pa-
tients were treated with metformin by 3 months. Pau et al11
conducted an open-label, interventional study of 36min treatment on body mass index.
Subgroup analyses
Overweight
I  25 kg/m2)
(n Z 55)
Nonobese
(BMI < 27 kg/m2)
(n Z 70)
Obese
(BMI  27 kg/m2)
(n Z 44)
ate
dard
)
p Estimate
(standard
error)
p Estimate
(standard
error)
p
3 (0.64) <0.0001 21.80 (0.32) <0.0001 32.22 (0.67) <0.0001
0.0003 0.28 0.0001
2 (0.50) 0.30 0.06 (0.31) 0.84 0.34 (0.58) 0.55
8 (0.50) 0.03 0.13 (0.30) 0.67 1.01 (0.59) 0.09
1 (0.51) 0.02 0.27 (0.30) 0.36 1.09 (0.62) 0.09
9 (0.54) 0.72 0.29 (0.33) 0.38 0.47 (0.63) 0.46
2-hour glucose and 2-hour insulin levels, which were statistically
e (shown in Table 1).
sterone.
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Figure 2 Change in 2-hour postload (A) glucose and (B) insulin levels before and after 6 months of metformin treatment. (A) The
plot shows 53.1% of polycystic ovary syndrome (PCOS) patients with decreased glucose levels, 45.7% with increased glucose levels,
and 1.2% with no change. The difference in the mean value of the 2-hour glucose level before and after metformin treatment was
not statistically significant (p Z 0.75). In addition, our subgroup analysis indicated that 22 of the 43 impaired glucose tolerance
patients (50%) became normal, whereas seven of the 71 patients (9.9%) without impaired glucose tolerance at the baseline showed
impaired glucose tolerance after treatment (see Supplementary Figure S2A online). (B) The plot shows 68.3% of PCOS patients with
decreased insulin levels and 31.7% with increased insulin levels. The difference in the mean value of the 2-hour insulin level before
and after metformin treatment was statistically significant (p Z 0.009). Our subgroup analysis further indicates that 21 of the 75
insulin resistance patients (27.7%) became normal, whereas 16 of the 39 patients (41.2%) without insulin resistance at the baseline
showed insulin resistance after treatment (see Supplementary Figure S2B online).
Table 4 Effect of metformin on 2-hour postload glucose and insulin levels within and between groups.
2-h glucose level (mg/dL)
Subgroups Baseline (mean  SD) After treatment
(mean  SD)
DID within group
(mean  SD, p)
DID between two groups
(mean  SD, p)
Normal (n Z 71) 104.3  18.3 107.7  26.3 3.7  3.4, p Z 0.29 21.4  9.9, p Z 0.03
Impaired glucose tolerance (n Z 43) 166.1  15.9 150.7  45.5 17.7  9.3, p Z 0.06
2-h insulin level (mIU/mL)
Subgroups Baseline
(mean  SD)
After treatment
(mean  SD)
DID within group
(mean  SD, p)
DID between two groups
(mean  SD, p)
Normal (n Z 39) 18.3  9.6 28.3  23.4 11.8  13.0, p Z 0.37 34.7  14.7, p Z 0.02
Insulin resistance (n Z 75) 97.1  61.9 74.6  63.4 22.9  6.6, p Z 0.0008
The DID analyses were adjusted for baseline blood pressure, metformin treatment duration, and adherence.
DID Z difference-in-difference; SD Z standard deviation.
86 H.-t. Ou et al.American women with PCOS (diagnosed using the NIH
criteria) from an academic medical center in the United
States and assessed the effects of metformin before and
after 12 weeks of metformin treatment. Li et al14 reported
the clinical effects of 6-month metformin treatment on 47
PCOS women from China.
In terms of body weight, the current study and those
mentioned earlier11,14,35 all showed that the patients’ BMI
significantly decreased after metformin treatment, but Fux
Otta et al34 did not find a similar trend. Regarding the 2-
hour postload glucose level from OGTT, both Fux Otta
et al34 and Pau et al11 reported a significant glycemicchange after metformin treatment; however, our study and
that of Li et al14 found a nonsignificant improvement,
whereas Saxena et al35 did not find a similar trend. Our
subgroup analysis further showed that over 50% of IGT pa-
tients became normal after metformin treatment, whereas
9.9% of PCOS women without IGT turned into IGT (see
Supplementary Figure S2A online). These results indicate
that metformin might be more effective in IGT cases than in
those without IGT.
Moreover, our study results and those of Saxena et al35
and Li et al14 demonstrated that the 2-hour insulin level
significantly lowered after metformin treatment. Our
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became normal after treatment, whereas 41% of PCOS
women without IR turned into IR (see Supplementary
Figure S2B online). However, the study results of Pau
et al11 and Fux Otta et al34 showed that metformin treat-
ment was not associated with improved insulin sensitivity
for PCOS women. The difference in metformin effect on
insulin sensitivity for PCOS women across studies might be
explained by different diagnostic techniques, cutoff points
for defining IR, and study population. Using the intravenous
glucose tolerance test, results in women with PCOS have
demonstrated no change in insulin sensitivity after
12 weeks to 3 months of metformin treatment.11,36,37 By
contrast, both Saxena et al’s35 results based on a cutoff
point of 2-hour insulin level over 41 mIU/mL and our study
results based on a cutoff value of 2-hour insulin level of
35 mIU/mL or more to determine IR showed improved in-
sulin sensitivity after metformin treatment. In Li et al’s
study,14 improved insulin sensitivity was found, as indicated
by the significant decrease in the HOMA score after
6 months of metformin treatment. In addition, using a
euglycemic hyperinsulinemic clamp was found to improve
insulin sensitivity.38,39 Moreover, Li et al’s study14 targeted
Chinese PCOS women from China and our study focused on
Taiwanese PCOS women, whereas the other aforemen-
tioned studies11,35,36e39 were from other countries/
ethnicity. Therefore, we suggest that future study should
be carried out to investigate any variations in metformin
efficacy for PCOS women due to different measuring ap-
proaches and countries/ethnicity.Metformin adherence among women with PCOS
Most previous research examined metformin adherence in
diabetes patients,16,17 but only little information is avail-
able about metformin use behavior in PCOS women. Li
et al’s study19 of 99 infertile PCOS women showed that 23%
of patients had good drug compliance as measured by the
MoriskyeGreen test, a patient self-reported medication
adherence questionnaire. Their study also showed that
PCOS women who had adverse drug reactions or experi-
enced inconvenient medical treatment (i.e., pill burden)
were likely to exhibit noncompliance. The present study
showed that, as measured by MPR, a pill count-based
medication adherence measure, PCOS women had satis-
factory medication adherence (mean of MPR > 0.85) as
compared with previously reported metformin adherence in
chronic disease patients (e.g., diabetes16,17). This is in part
because women with PCOS tend to be young. Most of our
participants had a high educational level and might have
had good health literacy in terms of their self-care and/or
health-seeking behaviors. Moreover, we found that XR
metformin prolonged patients’ treatment duration. It has
been reported that the side effects of metformin (e.g., GI
intolerance) may limit its use in diabetic patients.16,17 As
compared with conventional immediate-release metfor-
min, the XR metformin formulation reduces GI side effects
and allows once-daily dosing, reducing the pill burden for
patients and enhancing patients’ medication adherence,
thus ensuring the efficacy of treatment.24e26,40 Consistent
with these findings, Li et al’s study19 showed that PCOSpatients who had adverse drug reactions or experienced
inconvenient medical treatment (i.e., pill burden) were
likely to exhibit noncompliance. In addition, less adverse
drug events might lead to better drug compliance in PCOS
women.18 Therefore, XR metformin is an option for PCOS
women who experience GI intolerance due to the
immediate-release formulation or for those with poly-
pharmacy issues; additionally, this may improve their
adherence to metformin.
Approaches for diagnosing IR in Taiwanese women
with PCOS
Early detection of IR cases is important because such pa-
tients are prone to the risks of metabolic syndrome and
Type 2 diabetes.6 Because of lack of uniform diagnostic
measure to assess IR, the incidence of IR in PCOS women is
difficult to estimate,22 leading to discrepancies in IR rates
that varied with diagnostic approaches,41 inadequate
therapy, and misleading interpretations from the results of
treatment. Available diagnostic methods are expensive and
might not be convenient in practice. For routine practice, a
feasible method to determine IR in PCOS women is
needed.41 We compared the 2-hour postload insulin level
from OGTT with commonly used approaches, including
fasting insulin, HOMA, and QUICKI in diagnosing IR in
Taiwanese PCOS women. We sought to determine whether
the 2-hour insulin level from OGTT is a convenient tool for
screening IR cases in PCOS women. Our results imply that
the 2-hour insulin level from OGTT might be a feasible and
convenient method for screening IR in Taiwanese PCOS
women. Our additional analysis showed that 75.4%, 69.4%,
37.5%, and 14.9% of patients in this study (n Z 72) were
classified as having IR based on the 2-hour postload insulin
level from the OGTT, QUICKI, HOMA, and fasting insulin
results, respectively (see Supplementary Table S2 online).
As compared with gold standard (i.e., the euglycemic
clamp), the OGTT is less invasive and less expensive, re-
quires less time and skill, thus reducing costs of repeat
visits and is easier to apply in clinical practice. Therefore,
our study supports the results of Saxena et al’s22 study that
the 2-hour postload insulin level from the OGTT appears to
be a feasible maker to diagnose IR in PCOS women, espe-
cially in resource-restricted health care settings.
Potential limitations
Several limitations of this study need to be acknowledged.
First, this was an observational study without a comparison
group (i.e., without metformin treatment, oral contracep-
tives), and therefore, the results only note the improve-
ment after metformin treatment. Second, the present
study only used objective medication adherence measures
based on patients’ “refill pattern” (i.e., the length/dura-
tion of metformin treatment, MPR) to determine patients’
adherence. However, it is still uncertain whether patients
truly took the medication or even used it appropriately.
Subjective medication use/adherence measures such as the
Morisky medication adherence questionnaire should be
applied in future studies to control for potential impact of
patients’ medication behavior on clinical outcomes of
88 H.-t. Ou et al.interest. Third, all participants were from one medical
center in Taiwan. Future research is warranted to verify our
findings using a larger sample from different regions with
various education and socioeconomic statuses of Chinese
population. Fourth, Saxena et al22 used a cutoff value of 2-
hour postload insulin level greater than 41 mIU/mL to
determine IR in Indian PCOS women, whereas our study
selected a value of 2-hour insulin level of 35 mIU/mL or
more to determine IR in Taiwanese PCOS women. However,
until now no study has examined what cutoff point of 2-
hour postload insulin should be used to diagnose IR in
PCOS women. Therefore, if a single 2-hour postglucose in-
sulin level appears to be a reliable indicator of IR in PCOS
women, it is critical for further research to identify a
specific and sensitive cutoff point of 2-hour postload insulin
for determining IR. In addition, further research is needed
to evaluate if 2-hour postload insulin level is a dedicated
marker for monitoring treatment responses and determine
whether there is a liner relationship between 2-hour post-
load insulin level and metformin treatment.
Conclusion
This study of Taiwanese women with PCOS showed that
metformin significantly improved BMI and insulin sensi-
tivity, especially for overweight, IGT, and IR cases. Met-
formin could thus be considered as a suitable treatment for
Taiwanese PCOS patients who are overweight, IGT, or IR.
The 2-hour postload insulin level from OGTT appears to be a
promising approach for screening IR in ethnic Taiwanese
women with PCOS. Thus, therapeutic interventions (i.e.,
metformin) can be initiated, reducing future risk of
developing diabetes.Acknowledgments
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